AR025308A1 - Composiciones y metodos para tratar condiciones alergicas e inflamatorias con tos. - Google Patents

Composiciones y metodos para tratar condiciones alergicas e inflamatorias con tos.

Info

Publication number
AR025308A1
AR025308A1 ARP000104255A ARP000104255A AR025308A1 AR 025308 A1 AR025308 A1 AR 025308A1 AR P000104255 A ARP000104255 A AR P000104255A AR P000104255 A ARP000104255 A AR P000104255A AR 025308 A1 AR025308 A1 AR 025308A1
Authority
AR
Argentina
Prior art keywords
inflammatory conditions
methods
expectorant
compositions
sedating antihistamine
Prior art date
Application number
ARP000104255A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR025308A1 publication Critical patent/AR025308A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen métodos para tratar y/o prevenir condiciones alérgicas e inflamatorias con tos en humanos que requieran dicho tratamiento y/o prevencion, loscuales comprenden administrar una cantidad efectiva de una antihistamina no sedante encombinaci on con un expectorante; las modalidades que se prefierenincluyen aquellas en las que la antihistamina no sedante es loratadina y el expectorante es ambroxol; se proveen también composiciones farmacéuticas novedosaspara tratar y/o prevenircondiciones alérgicas e inflamatorias con tos en humanos, las cuales comprenden una cantidad efectiva de una antihistamina no sedanteen combinacion con un expectorante y un vehículo farmacéuticamente aceptable.
ARP000104255A 2000-03-30 2000-08-17 Composiciones y metodos para tratar condiciones alergicas e inflamatorias con tos. AR025308A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19331000P 2000-03-30 2000-03-30

Publications (1)

Publication Number Publication Date
AR025308A1 true AR025308A1 (es) 2002-11-20

Family

ID=22713096

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104255A AR025308A1 (es) 2000-03-30 2000-08-17 Composiciones y metodos para tratar condiciones alergicas e inflamatorias con tos.

Country Status (13)

Country Link
CN (1) CN1422162A (es)
AR (1) AR025308A1 (es)
AU (2) AU4786701A (es)
BR (1) BR0003648A (es)
CO (1) CO5200779A1 (es)
CR (1) CR6232A (es)
NZ (1) NZ520826A (es)
PA (1) PA8500101A1 (es)
PE (1) PE20010576A1 (es)
SG (1) SG96611A1 (es)
TW (1) TWI243671B (es)
WO (1) WO2001074341A2 (es)
ZA (1) ZA200102605B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005123052A1 (fr) * 2004-06-18 2005-12-29 Jiangsu Hengrui Medicine Co., Ltd. Composition medicamenteuse contenant de l'ambroxol et de l'erdosteine ou de l'acetylcysteine
CN1323662C (zh) * 2004-06-18 2007-07-04 江苏恒瑞医药股份有限公司 含有氨溴索和厄多司坦或乙酰半胱氨酸的药物组合物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783465A (en) * 1984-04-09 1988-11-08 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4829064A (en) * 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
BR9407414A (pt) * 1993-09-07 1996-11-12 Procter & Gamble Composições contendo um sal de aminoácido de agente antiinflamatório não-esteroide de ácido propiônico e pelo menos um descongestionante um expectorante um anti-histamina e um antitussivo
US6160020A (en) * 1996-12-20 2000-12-12 Mcneill-Ppc, Inc. Alkali metal and alkaline-earth metal salts of acetaminophen

Also Published As

Publication number Publication date
CN1422162A (zh) 2003-06-04
ZA200102605B (en) 2001-10-03
WO2001074341A2 (en) 2001-10-11
PA8500101A1 (es) 2002-09-17
WO2001074341A3 (en) 2002-05-16
AU4786701A (en) 2001-10-15
TWI243671B (en) 2005-11-21
NZ520826A (en) 2004-07-30
BR0003648A (pt) 2002-01-02
CO5200779A1 (es) 2002-09-27
SG96611A1 (en) 2003-06-16
CR6232A (es) 2008-12-01
AU2001247867B2 (en) 2005-09-01
PE20010576A1 (es) 2001-05-08

Similar Documents

Publication Publication Date Title
AR028296A1 (es) Metodos sinergisticos y composiciones para el tratamiento del cancer
UY28041A1 (es) Metodos de dosis bajas para el tratamiento de trastornos en los cuales la actividad del tnfa es perjudicial.
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
NO993847D0 (no) Fremgangsmåter og sammensetninger for behandling av allergisk astma og andre sykdommer som anvender deskarboetoksyloratadin
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
NO20034094D0 (no) Sammensetninger som omfatter et antidiar±middel og et epotilon eller et epotilonderivat
CR6210A (es) Composiciones de celecoxib
DK1071417T3 (da) Anvendelse af cannabidiol som anti-inflammatorisk middel
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
ECSP003807A (es) Composiciones valdecoxib
ECSP045153A (es) Metodo y composición para aumentar la potencia de un analgésico de narcotico.
GEP20053657B (en) Cell Adhesion-Inhibiting Antiinflammatory and Immune-Suppressive Compounds, Pharmaceutical Compositions Thereof
AR008799A1 (es) Composicion de vacuna para prevenir o tratar el paludismo; uso de dicha composicion para elaborar medicamentos y metodo para dicha profilaxis y dichotratamiento
NO20054216L (no) Anvendelse av dipyridamol i kombinasjon med acetylsalisylsyre og en angiotensin II antagonist for forhindring av slag
ATE406159T1 (de) Behandlung von hyperlipidämie
AR028502A1 (es) Tratamiento de condiciones inflamatorias alérgicas
AR025308A1 (es) Composiciones y metodos para tratar condiciones alergicas e inflamatorias con tos.
DK0799618T3 (da) Anvendelse af alpha1-adrenoreceptor-antagonister i fremstillingen af et medikament til forebyggelsen og behandlingen af cancer
CO5580773A2 (es) Rosuvastatina en estados pre dementes
RS50681B (sr) Kombinacija taksana i ciklin-zavisne kinaze
MX9302985A (es) Composicion farmaceutica para el tratamiento y la profilaxis de la ansiedad.
AR030660A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12
CL2006002620A1 (es) Composicion para la prevencion y tratamiento de infecciones causadas por coccidia en animales que consiste en yema con inmunoglobulas anti-eimeria, agua y un conservador; y metodo para la prevencion de infecciones causadas por parasitos coccidia que comprende la administracion oral de una o mas inmunoglobulinas anti eimeria.
DE60304678D1 (de) Idraparinux (sanorg 34006) zur behandlung und sekundärprophylaxe von thromboembolien bei patienten mit tiefer venenthrombose

Legal Events

Date Code Title Description
FA Abandonment or withdrawal